An Overview of ABT-199 for the Treatment of CLL
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with CLL.
Clinical Pearls
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with chronic lymphocytic leukemia (CLL).
- ABT-263 demonstrated significant activity in CLL, though caused thrombocytopenia
- ABT-199 has not had thrombocytopenia issues, but is so potent that it has had problems with tumor lysis
- ABT-199 demonstrated an 80-85% nodal response in an ongoing phase I trial (52 patients)
- All 52 patients in the trial experienced a 50% reduction in lymphocyte count
- ABT-199 has demonstrated efficacy in patients with a 17p deletion and may clear bone marrow more effectively than kinase inhibitors
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
